Katya Korol

1 week ago | kevinmd.com | Julie Craig |Katya Korol |Sarah Fraser |Martha Rosenberg

Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes!Health care executive Gavin Magaha discusses his article “Advancing drug discount programs starts with collaboration and clarity.” He outlines how the 340B drug discount program, established over 30 years ago, has not evolved with modern health care delivery, leading to complexity, poorly defined standards, compliance issues, and misaligned incentives that hinder its original intent to serve vulnerable patients.

Oct 5, 2024 | kevinmd.com | Martha Rosenberg |Judy Salz |Julie Craig |Katya Korol

Having worked as a copywriter and creative director at some of the world’s top ad agencies, including McCann Erickson (now McCann Worldgroup), I am vehemently critical of new advertising. Why? I know the tricks and how they manipulate well — think the old TV series Mad Men. Leading the list of ads that I hate are direct-to-consumer (DTC) drug ads which began in the late 1990s. I am especially critical of them because I personally attended medical school for a while.

Nov 5, 2023 | kevinmd.com | Amarish Dave |Judy Salz |Julie Craig |Katya Korol

As doctors, we are highly skilled in our respective specialties, but when it comes to managing our finances and investments, we may encounter unique challenges. One common pitfall is the tendency to invest heavily in medical stocks or health care-related assets due to familiarity and overconfidence. Just because we know a disease or drug doesn’t mean we can make a good decision on the stock of a company. Even if the drug is profitable, it doesn’t mean overall it will impact the stock price.